Effect of sodium-glucose cotransporter 2 inhibitors on bone metabolism in patients with type 2 diabetes mellitus
AbstractType 2 diabetes mellitus (T2DM) increases the risk of low-trauma fractures despite bone mineral density (BMD) is normal or even elevated. The bone microarchitecture can deteriorate due to the influence of hyperglycemia and pro-inflammatory cytokines, as well as electrolyte disorders. On the other hand, chronic complications of DM (diabetic polyneuropathy, retinopathy) may lead to an increased risk of falls. The role of hypoglycemic drugs in bone metabolism is currently the subject of research. The analysis of the effect of sodium-glucose cotransporter type 2 inhibitors on bone metabolism parameters in patients T2DM did not show a significant effect of these drugs on laboratory parameters of bone remodeling and as well as on dual-energy X-ray absorptiometry parameters.
Keywords:diabetes mellitus; osteoporosis; sodium-glucose cotransporter type 2 inhibitors
Funding. The study had no sponsor support.
Conflict of interest. The author declares no conflict of interest.
For citation: Timkina N.V., Tikhomirova P.A. Effect of sodium-glucose cotransporter‑2 inhibitors on bone metabolism in patients with type 2 diabetes mellitus. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2023; 12 (3): 75–7. (in Russian)
DOI: https://doi.org/10.33029/2304-9529-2023-12-3-75-77 (in Russian)